keyword
MENU ▼
Read by QxMD icon Read
search

Royal marsden

keyword
https://www.readbyqxmd.com/read/29748008/predicting-outcomes-in-patients-with-advanced-non-small-cell-lung-cancer-enrolled-in-early-phase-immunotherapy-trials
#1
Hossein Maymani, Kenneth Hess, Roman Groisberg, David S Hong, Aung Naing, Sarina Piha-Paul, Filip Janku, Siqing Fu, Apostolia M Tsimberidou, Shubham Pant, Daniel Karp, Shuang Liu, Ming Sun, John Heymach, George Simon, Funda Meric-Bernstam, Vivek Subbiah
OBJECTIVES: Immunotherapy (IO) has altered the non-small cell lung cancer (NSCLC) therapeutic landscape. However, the majority of patients do not respond to immune-checkpoint blockade, and subsequently either receive further chemotherapy or are referred for clinical trials. Here we examined the outcomes and predictors of response to IO in early phase clinical trials. MATERIALS AND METHODS: We analyzed the records of 74 patients with metastatic NSCLC that were enrolled on phase 1 IO trials within MD Anderson Cancer Center from 1/2010 to 7/2017...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29614442/the-role-of-genomic-profiling-in-adolescents-and-young-adults-ayas-with-advanced-cancer-participating-in-phase-i-clinical-trials
#2
Terri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, Stan B Kaye, Udai Banerji, Juanita S Lopez, Johann de Bono, Winette T A van der Graaf, Angela J George
INTRODUCTION: Adolescents and young adults (AYAs) diagnosed with cancer between ages 15-39 years may harbour germline variants associated with cancer predisposition. Such variants represent putative therapeutic targets, as may somatic variants in the tumour. Germline and tumour molecular profiling is increasingly utilised to facilitate personalisation of cancer treatment in such individuals. AIM: Considering AYAs with advanced solid tumours managed in a specialist drug development unit (DDU), the aims of this study were to investigate the use and impact of: 1...
March 31, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29462132/development-of-a-prognostic-scoring-system-for-patients-with-advanced-cancer-enrolled-in-immune-checkpoint-inhibitor-phase-1-clinical-trials
#3
Shiraj Sen, Kenneth Hess, David S Hong, Aung Naing, Sarina Piha-Paul, Filip Janku, Siqing Fu, Ishwaria M Subbiah, Holly Liu, Rahil Khanji, Le Huang, Shhyam Moorthy, Daniel D Karp, Apostolia Tsimberidou, Funda Meric-Bernstam, Vivek Subbiah
This corrects the article DOI: 10.1038/bjc.2017.85.
March 20, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29429804/clinical-outcome-of-prostate-cancer-patients-with-germline-dna-repair-mutations-retrospective-analysis-from-an-international-study
#4
Joaquin Mateo, Heather H Cheng, Himisha Beltran, David Dolling, Wen Xu, Colin C Pritchard, Helen Mossop, Pasquale Rescigno, Raquel Perez-Lopez, Verena Sailer, Michael Kolinsky, Ada Balasopoulou, Claudia Bertan, David M Nanus, Scott T Tagawa, Heather Thorne, Bruce Montgomery, Suzanne Carreira, Shahneen Sandhu, Mark A Rubin, Peter S Nelson, Johann S de Bono
BACKGROUND: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear. OBJECTIVE: To determine whether gDDRm status impacts benefit from established therapies in mPC. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective, international, observational study. Medical records were reviewed for 390 mPC patients with known gDDRm status...
May 2018: European Urology
https://www.readbyqxmd.com/read/29242596/total-energy-expenditure-and-vigorous-intensity-physical-activity-are-associated-with-reduced-odds-of-reclassification-among-men-on-active-surveillance
#5
David E Guy, Avi Vandersluis, Laurence H Klotz, Neil Fleshner, Alexander Kiss, Chris Parker, Vasundara Venkateswaran
BACKGROUND: Research examining the association between physical activity (PA) and prostate cancer (PCa) has accumulated; however, few studies have examined this association in the context of active surveillance. The current study examines this among men initially diagnosed with favorable-risk PCa and managed by active surveillance at Sunnybrook Health Sciences Centre in Canada and the Royal Marsden Hospital in the United Kingdom. METHODS: Participants completed a questionnaire on daily participation in non-leisure, transport, and recreational PA...
December 14, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29191429/successful-repatriation-of-breast-cancer-surveillance-for-high-risk-women-to-the-uk-national-health-service-breast-screening-programme
#6
Terri P McVeigh, Jennifer Wiggins, Simon Ward, Zoe Kemp, Angela J George
BACKGROUND: Since April 2013, the UK's National Health Service Breast Screening Programme (NHSBSP) centers have been obliged to provide services for women at the highest risk of breast cancer, including those carrying highly penetrant single gene mutations (BRCA1, BRCA2, TP53). Since then, such individuals previously undergoing surveillance in the Royal Marsden Hospital were referred to their local NHSBSP centers. We aimed to assess patient experience of surveillance provided by local NHSBSP services at 1 and 3 years after repatriation...
October 28, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29119842/outcomes-following-front-line-chemotherapy-in-peripheral-t-cell-lymphoma-10-year-experience-at-the-royal-marsden-and-the-christie-hospital
#7
Mary Gleeson, Clare Peckitt, David Cunningham, Adam Gibb, Eliza A Hawkes, Morgan Back, Binnaz Yasar, Kate Foley, Rebecca Lee, Joanna Dash, Hannah Johnson, Catherine O'Hara, Andrew Wotherspoon, Ayoma Attygalle, Lia Menasce, Patrick Shenjere, Mike Potter, Mark E Ethell, Claire Dearden, John Radford, Ian Chau, Kim Linton
We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13...
November 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29026057/pathological-outcome-for-chinese-patients-with-low-risk-prostate-cancer-eligible-for-active-surveillance-and-undergoing-radical-prostatectomy-comparison-of-six-different-active-surveillance-protocols
#8
C F Tsang, J Hl Tsu, T Ct Lai, K W Wong, B Sh Ho, A Tl Ng, W K Ma, M K Yiu
INTRODUCTION: Active surveillance is one of the therapeutic options for the management of patients with low-risk prostate cancer. This study compared the performance of six different active surveillance protocols for prostate cancer in the Chinese population. METHODS: Patients who underwent radical prostatectomy for prostate cancer from January 1998 to December 2012 at a university teaching hospital in Hong Kong were reviewed. Six active surveillance protocols were applied to the cohort...
December 2017: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/28942009/comparison-of-11-active-surveillance-protocols-in-contemporary-european-men-treated-with-radical-prostatectomy
#9
Sami-Ramzi Leyh-Bannurah, Pierre I Karakiewicz, Paolo Dell'Oglio, Alberto Briganti, Jonas Schiffmann, Raisa S Pompe, Guido Sauter, Thorsten Schlomm, Hans Heinzer, Hartwig Huland, Markus Graefen, Lars Budäus
BACKGROUND: The aim of this study was to compare 11 active surveillance (AS) protocols in contemporary European men treated with radical prostatectomy (RP) at the Martini-Clinic Prostate Cancer Center. PATIENTS AND METHODS: Analyzed were 3498 RP patients, from 2005 to 2016, who underwent ≥ 10 core biopsies and fulfilled at least 1 of 11 examined AS entry definitions. We tested proportions of AS eligibility, ineligibility, presence of primary Gleason 4/5, upstage, and combinations thereof at RP, as well as 5-year biochemical recurrence-free survival (BFS)...
August 31, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28833867/development-and-responses-of-brain-metastases-during-treatment-with-trastuzumab-emtansine-t-dm1-for-her2-positive-advanced-breast-cancer-a-single-institution-experience
#10
Alicia Okines, Tazia Irfan, Komel Khabra, Ian Smith, Mary O'Brien, Marina Parton, Jill Noble, Susie Stanway, Navita Somaiah, Alistair Ring, Stephen Johnston, Nicholas Turner
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that does not cross an intact blood-brain barrier. In the EMILIA trial of T-DM1 vs capecitabine/lapatinib for HER2 positive advanced breast cancer, all patients had baseline brain imaging, and 9/450 (2%) of patients with negative baseline imaging developed new brain disease during T-DM1. We assessed the frequency of brain progression in clinical practice, without routine baseline imaging. We undertook a retrospective study of all patients treated with T-DM1 at the Royal Marsden Hospital from 2011 to 2016...
August 22, 2017: Breast Journal
https://www.readbyqxmd.com/read/28732480/metformin-and-longevity-metal-a-window-of-opportunity-study-investigating-the-biological-effects-of-metformin-in-localised-prostate-cancer
#11
Danielle Crawley, Ashish Chandra, Massimo Loda, Cheryl Gillett, Paul Cathcart, Ben Challacombe, Gary Cook, Declan Cahill, Aida Santa Olalla, Fidelma Cahill, Gincy George, Sarah Rudman, Mieke Van Hemelrijck
BACKGROUND: Metformin is a biguanide oral hypoglycaemic agent commonly used for the treatment of type 2 diabetes mellitus. In addition to its anti-diabetic effect, metformin has also been associated with a reduced risk of cancer incidence of a number of solid tumours, including prostate cancer (PCa). However, the underlying biological mechanisms for these observations have not been fully characterised in PCa. One hypothesis is that the indirect insulin lowering effect may have an anti-neoplastic action as elevated insulin and insulin like growth factor - 1 (IGF-1) levels play a role in PCa development and progression...
July 21, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28694034/insertion-and-deletion-derived-tumour-specific-neoantigens-and-the-immunogenic-phenotype-a-pan-cancer-analysis
#12
Samra Turajlic, Kevin Litchfield, Hang Xu, Rachel Rosenthal, Nicholas McGranahan, James L Reading, Yien Ning S Wong, Andrew Rowan, Nnennaya Kanu, Maise Al Bakir, Tim Chambers, Roberto Salgado, Peter Savas, Sherene Loi, Nicolai J Birkbak, Laurent Sansregret, Martin Gore, James Larkin, Sergio A Quezada, Charles Swanton
BACKGROUND: The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated whether the frameshift nature of indel mutations, which create novel open reading frames and a large quantity of mutagenic peptides highly distinct from self, might contribute to the immunogenic phenotype. METHODS: We analysed whole-exome sequencing data from 5777 solid tumours, spanning 19 cancer types from The Cancer Genome Atlas...
August 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28672850/quality-of-life-qol-during-screening-for-phase-1-trial-studies-in-patients-with-advanced-solid-tumors-and-its-impact-on-risk-for-serious-adverse-events
#13
Sidra Anwar, Wei Tan, Chi-Chen Hong, Sonal Admane, Askia Dozier, Francine Siedlecki, Amy Whitworth, Ann Marie DiRaddo, Dawn DePaolo, Sandra M Jacob, Wen Wee Ma, Austin Miller, Alex A Adjei, Grace K Dy
Background: Serious adverse events (SAEs) and subject replacements occur frequently in phase 1 oncology clinical trials. Whether baseline quality-of-life (QOL) or social support can predict risk for SAEs or subject replacement among these patients is not known. Methods: Between 2011-2013, 92 patients undergoing screening for enrollment into one of 22 phase 1 solid tumor clinical trials at Roswell Park Cancer Institute were included in this study. QOL Questionnaires (EORTC QLQ-C30 and FACT-G), Medical Outcomes Study Social Support Survey (MOSSSS), Charlson comorbidity scores (CCS) and Royal Marsden scores (RMS) were obtained at baseline...
June 26, 2017: Cancers
https://www.readbyqxmd.com/read/28666422/the-role-of-hormonal-therapy-in-patients-with-relapsed-high-grade-ovarian-carcinoma-a-retrospective-series-of-tamoxifen-and-letrozole
#14
Angela George, Jennifer McLachlan, Nina Tunariu, Chiara Della Pepa, Cristina Migali, Martin Gore, Stan Kaye, Susana Banerjee
BACKGROUND: Hormonal therapy is used as a treatment option in high-grade ovarian carcinoma (HGOC), but the role and choice of treatment remains unclear. Agents used include tamoxifen and aromatase inhibitors. Our aim was to evaluate the efficacy of tamoxifen (T) and letrozole (L) in HGOC in clinical practice and investigate factors influencing clinical outcome. METHODS: A retrospective review of patients with relapsed HGOC treated with either tamoxifen or letrozole at the Royal Marsden Hospital between 2007 and 2012 was performed...
June 30, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28571827/effect-on-overall-survival-of-locoregional-treatment-in-a-cohort-of-de-novo-metastatic-prostate-cancer-patients-a-single-institution-retrospective-analysis-from-the-royal-marsden-hospital
#15
Diletta Bianchini, David Lorente, Pasquale Rescigno, Zafeiris Zafeiriou, Elena Psychopaida, Hazel O'Sullivan, Mervyn Alaras, Michael Kolinsky, Semini Sumanasuriya, Mariane Sousa Fontes, Joaquin Mateo, Raquel Perez Lopez, Nina Tunariu, Nikolaos Fotiadis, Pardeep Kumar, Alison Tree, Nicholas Van As, Vincent Khoo, Chris Parker, Rosalind Eeles, Alan Thompson, David Dearnaley, Johann S de Bono
BACKGROUND: The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on overall survival (OS) hypothesizing that this could improve outcome through better local disease control and the induction of an antitumor immune response (abscopal effect). PATIENTS AND METHODS: M1 at diagnosis PCa patients referred to the Prostate Targeted Therapy Group at the Royal Marsden between June 2003 and December 2013 were identified...
October 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28493401/the-effect-of-adjuvant-chemotherapy-on-survival-and-recurrence-after-curative-rectal-cancer-surgery-in-patients-who-are-histologically-node-negative-after-neoadjuvant-chemoradiotherapy
#16
D L H Baird, Q Denost, C Simillis, G Pellino, S Rasheed, C Kontovounisios, P P Tekkis, E Rullier
AIM: The aim of this study was to evaluate whether adjuvant chemotherapy will affect recurrence rate or disease-free and overall survival in patients with rectal adenocarcinoma who were staged with MRI node-positive disease (mrN+) preoperatively. These patients underwent neoadjuvant chemoradiotherapy with curative rectal cancer surgery and their pathological staging was negative for nodal disease (ypN0). There is no consensus on the role of adjuvant chemotherapy in such patients. METHOD: Patients who received neoadjuvant chemoradiotherapy and underwent curative rectal cancer surgery for rectal adenocarcinoma staged as [mrTxN+M0] on MRI staging and who on pathological staging were found to be [ypTxN0M0] were retrospectively identified from January 2008 December 2012 from two tertiary referral centres (Royal Marsden Hospital, London and Saint-Andre Hospital, Bordeaux)...
November 2017: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
https://www.readbyqxmd.com/read/28463962/nomogram-based-prediction-of-survival-in-patients-with-advanced-oesophagogastric-adenocarcinoma-receiving-first-line-chemotherapy-a-multicenter-prospective-study-in-the-era-of-trastuzumab
#17
MULTICENTER STUDY
A Custodio, A Carmona-Bayonas, P Jiménez-Fonseca, M L Sánchez, A Viudez, R Hernández, J M Cano, I Echavarria, C Pericay, M Mangas, L Visa, E Buxo, T García, A Rodríguez Palomo, F Álvarez Manceñido, A Lacalle, I Macias, A Azkarate, A Ramchandani, A Fernández Montes, C López, F Longo, R Sánchez Bayona, M L Limón, A Díaz-Serrano, A Hurtado, R Madero, C Gómez, J Gallego
BACKGROUND: To develop and validate a nomogram and web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma (AOA) patients undergoing first-line combination chemotherapy. METHODS: Nine hundred twenty-four AOA patients treated at 28 Spanish teaching hospitals from January 2008 to September 2014 were used as derivation cohort. The result of an adjusted-Cox proportional hazards regression was represented as a nomogram and web-based calculator...
June 6, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28447240/relationship-between-ihc4-score-and-response-to-neo-adjuvant-chemotherapy-in-estrogen-receptor-positive-breast-cancer
#18
A Sheri, I E Smith, M Hills, R L Jones, S R Johnston, M Dowsett
AIMS: To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response to neo-adjuvant chemotherapy in ER-positive (ER+) breast cancer; (ii) provides more predictive information than Ki67 alone. METHODS: 113 patients with ER+ primary breast cancer treated with neo-adjuvant chemotherapy at the Royal Marsden Hospital between 2002 and 2010 were included in the study. Pathologic assessment of the excision specimen was made for residual disease...
July 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28444724/the-morality-of-good-end-of-life-care-in-critical-care
#19
EDITORIAL
Natalie Pattison
No abstract text is available yet for this article.
May 2017: Nursing in Critical Care
https://www.readbyqxmd.com/read/28426103/neurotoxicity-from-immune-checkpoint-inhibition-in-the-treatment-of-melanoma-a-single-centre-experience-and-review-of-the-literature
#20
REVIEW
L Spain, G Walls, M Julve, K O'Meara, T Schmid, E Kalaitzaki, S Turajlic, M Gore, J Rees, J Larkin
Background: Treatment with immune checkpoint inhibitors (ICPi) has greatly improved survival for patients with advanced melanoma in recent years. Anti-CTLA-4 and anti-PD1 antibodies have been approved following large Phase III trials. Immune-related neurological toxicity of varying severity has been reported in the literature. The cumulative incidence of neurotoxicity among ipilimumab, nivolumab and pembrolizumab is reported as <1% in published clinical trials. We aimed to identify the incidence of neurotoxicity in our institution across anti-CTLA4 and anti-PD-1 antibodies, including the combination of ipilimumab with nivolumab...
February 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
46646
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"